Longitudinal human immunodeficiency virus type 1 load in the Italian seroconversion study: Correlates and temporal trends of virus load

Journal of Infectious Diseases

Volumn 180, Issue 4, 1999, Pages 1018-1024

  Lyles, Cynthia M ^a   Dorrucci, Maria ^b   Vlahov, David ^a   Pezzotti, Patrizio ^b   Angarano, Gioacchino ^c   Sinicco, Alessandro ^d   Alberici, Francesco ^e   Alcorn, Timothy M ^f   Vella, Stefano ^b   Rezza, Giovanni ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c Clinic of Infectious Diseases   (Italy)

^d Infectious Disease Clinics of Torino   (Italy)

^e Infect Disease Clinics of Piacenza   (Italy)

^f LABORATORY CORPORATION OF AMERICA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SEROCONVERSION; SEX DIFFERENCE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGE FACTORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV ANTIBODIES; HIV SEROPOSITIVITY; HIV-1; HUMANS; ITALY; LONGITUDINAL STUDIES; MALE; RNA, VIRAL; TIME FACTORS; VIRAL LOAD;

EID: 0033383071     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314980     Document Type: Article

References (21)

1. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946-54.
2. Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4 cell count. JAMA 1998; 279:35-40.
3. Mellors JW, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-9.
4. Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA 1995;274:554-8.
5. Katzenstein TL, Pedersen C, Nielsen C, Lundgren JD, Jakobsen PH, Gerstoft J. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 1996; 10:167-73.
6. Pedersen C, Katzenstein T, Nielsen C, Lundgren JD, Gerstoft J. Prognostic value of serum HIV-RNA levels at virologie steady state after seroconversion: relation to CD4 cell count and clinical course of primary infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:93-9.
7. O'Brien TR, Rosenberg PS, Yellin F, Goedert JJ. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:155-61.
8. Piatak M Jr, Sung MS, Yang LC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259:1749-54.
9. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-4.
10. Pantaleo G, Graziosi C, Demurest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-8.
11. Paxton WB, Coombs RW, McElrath MJ, et al. Longitudinal analysis of quantitative virologie measures in human immunodeficiency virus infected subjects with ≥400 CD4 lymphocytes: implications for applying measurements to individual patients. J Infect Dis 1997; 175:247-54.
12. Bruisten SM, Frissen PHJ, Van Swieten P, et al. Prospective longitudinal analysis of viral load and surrogate markers in relation to clinical progression in HIV type 1 infected persons. AIDS Res Hum Retroviruses 1997; 13:327-35.
13. Keet IPM, Janssen M, Veugelers PJ, et al. Longitudinal analysis of CD4 T cell counts, T cell reactivity, and human immunodeficiency virus type 1 RNA levels in persons remaining AIDS-free despite CD4 cell counts <200 for >5 years. J Infect Dis 1997; 176:665-71.
14. Pezzotti P, Rezza G, Lazzarin A, et al. Influence of gender, age, and transmission category on the progression from HIV seroconversion to AIDS. J Acquir Immune Defic Syndr 1992;5:745-7.
15. Pezzotti P, Phillips N, Dorrucci M, et al. Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. BMJ 1996;313:583-6.
16. Littell RC. Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. Cary, NC: SAS Institute, 1996.
17. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993; 328:327-35.
18. Sterling TR, Lyles CM, Vlahov D, Astemborski J, Margolick JB, Quinn TC. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters. J Infect Dis 1999; 180:666-72.
19. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic und immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996; 335:1091-8.
20. Farzadegan H, Hoover DR, Astemborski J, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet 1998;352:1510-4.
21. Margolick JB, Munoz A, Vlahov D, et al. Direct comparison of the relationship between clinical outcome and change in CD4 lymphocytes in human immunodeficiency virus positive homosexual men and injecting drug users. Arch Intern Med 1994; 154:869-75.